Bergen, 10 October 2018 – reference is made to the previous announcement on 24 September 2018 regarding the disclosure of large shareholdings in relation to the rights issue in PCI Biotech Holding ASA (the "Company" or "PCI Biotech"). In the rights issue Myrlid AS, a company controlled by Kjetil Myrlid Aasen, has subscribed and been allocated 1,300,000 new shares in the Company. As a result of the transaction, Myrlid AS has become the owner of shares representing more than 5 % of the share capital. After the transaction, Myrlid AS owns 2,260,000 shares in PCI Biotech, equal to 6.11 % of the current outstanding shares and votes in the Company.

Aasen, including close associates, holds 3,055,000 shares in PCI Biotech, equal to 8.26 % of the current outstanding shares and votes in the Company.

This notification is based on the share capital of PCI Biotech being NOK 110,984,670 divided on 36,994,890 shares.